Q-omics provides the consensus-scored CNN2P9 profile across patient tissues and cancer cell-line models. CNN2P9 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CNN2P9 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, CNN2P9 RNA expression shows 18,475 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where CNN2P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNN2P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNN2P9 survival associations across molecular data types. CNN2P9 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNN2P9 RNA expression–survival associations across cancer types. High CNN2P9 expression shows unfavorable associations in ACC and MESO, but favorable associations in KIRC, HNSC, SKCM and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CNN2P9 RNA expression.
This table summarizes CNN2P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CNN2P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNN2P9 shows lower tumor expression in KICH and BRCA and higher tumor expression in KIRC, KIRP, CHOL and LIHC. The KIRC box plot shows higher CNN2P9 RNA expression in tumor versus normal tissue (log2 FC = +0.334, t-test p < 0.001).
This table shows molecular features associated with CNN2P9 in patient tissues and cancer cell lines. In patient samples, CNN2P9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
